Guangrong Zheng

This paper identifies IKKβ and NR4A1 as drivers of AML and develops a PROTAC to degrade them, showing potent cytotoxicity and reduced leukemia progression in mice.

This study shows that clearing senescent cells with 753b improves bone marrow aging by restoring HSC function and niche balance.

This paper shows that combining BCL-xL PROTAC and mTOR inhibitor with KRASG12D inhibitor enhances apoptosis and overcomes resistance in PDAC.

This paper demonstrates that microfluidic droplet-based electroporation (microDES) enhances PROTAC drug delivery via extracellular vesicles, improving therapeutic efficacy and safety in a TNBC mouse model.

This study identifies OXPHOS-high quiescent triple-negative breast cancer cells that survive chemotherapy and depend on BCL-XL for survival, showing that targeting BCL-XL enhances chemotherapy efficacy.

This study shows that combining radiation with Bcl-xL inhibition reduces tumor growth in preclinical models of H3K27M-altered diffuse midline glioma.

This paper evaluates a dual BCL-xL/BCL-2 degrader, 753b, showing it effectively reduces tumor viability and growth in SCLC models while avoiding platelet toxicity seen with navitoclax.

DyScore improves protein-ligand binding prediction by incorporating dynamic features into a boosting model, achieving better performance than existing methods.